Why is FDA Quiet About the Off-Label Promotion of Ozempic? Ozempic Vs Viagra

The media frenzy driven by social media posts describing the off-label use of Ozempic and similar drugs for weight loss has seemingly caught the FDA off-guard. This is a classic case of where off-label promotion of a product by sources independent of the manufacturers has yielded excessive riches for the manufacturers. The hype around weight … Read more

Digital Health Company’s Bankruptcy Highlights the Challenges of DM Products

The bankruptcy of Pear Therapeutics serves as a cautionary tale for the digital medicine industry. The Boston-based startup had raised over $200 million in funding, developed digital therapeutics for the treatment of substance use disorder and other mental health conditions, and got them through FDA approval. However, it was unable to yield returns it projected … Read more

FDA Finalizes Risk-Based Monitoring Guidance with Practical Advice

The final FDA guidance on risk-based monitoring (RBM) for clinical trials released this week expands on the advice given in the draft guidance from almost 10 years ago with a goal to reduce overall in-person site monitoring visits and increase reliance on centralized remote monitoring. Overall, this is not new information but confirmation of prevailing … Read more

Disclose Possibility of Early Termination in Informed Consent: IRB

A clinical trial may terminate early for a number of reasons unrelated to the safety of the investigational product. A survey of informed consent documents found that most of them do not acknowledge the possibility of early termination of the trial and the potential direct or indirect consequences for the participants for the same. Should … Read more

Why Do We Still Need Primate Toxicity Studies?

Since the beginning of the pandemic, there has been an acute shortage of monkeys for non-clinical research. Recently, due to increase in smuggling of long-tailed macaques, federal regulator started blocking imports from Cambodia, further aggravating the shortage of animals and a resulting increase in the cost and delays in research. But how big is this … Read more

FDA “New” Policy For Medical Devices with Cybersecurity Issues

Medical devices with software that connects to the internet and creates a potentially unaddressed cybersecurity vulnerability will be rejected by the FDA, starting 29 March 2023. The policy, which has been tacitly in effect since 2014 via Guidance Documents, is now being formalized into a Refuse-to-File (RTF) criteria. So, what’s new here? Many medical devices … Read more

FDA updates the Medical Foods Guidance

This week FDA updated its Medical Foods guidance to clarify and expand on its previous guidance from 2016. The main update is regarding the requirement for allergen warning on medical food labels but there are several other pointers in the guidance about medical foods to answer common questions from consumers and industry alike. Medical foods … Read more

Animal Drug Approval Based Only on Published Literature is Challenging

FDA allows animal drug approvals based entirely on published literature provided the selected publications adequately justify the specific claims in the market approval application and meets well-established scientific quality standards. Published literature lacks several quality standards essential for regulatory acceptance as sole evidence. FDA’s latest guidance on the topic lists those challenges and suggests ways … Read more

FDA Updates the Guidance for Electronic Records in Clinical Trials

Electronic Records are an integral part of clinical practice and hence also of clinical trial source documents. In its 2017 Guidance on using electronic records in clinical trials FDA provided several suggestions on best practices for sponsors and clinical research organizations. This week FDA released an updated Guidance that expands on the original guidance to … Read more